Evommune (EVMN) Consolidated Net Income (2024 - 2026)

Evommune (EVMN) has 3 years of Consolidated Net Income data on file, last reported at -$21.7 million in Q1 2026.

• Quarterly Consolidated Net Income fell 50.18% year-over-year to -$21.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$76.9 million (changed N/A YoY) and the FY2025 annual result came in at -$77.8 million, down 16.45% from the prior year.
• Consolidated Net Income rose to -$21.7 million in Q1 2026 per EVMN's latest filing, from -$28.3 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$12.5 million in Q3 2025 and bottomed at -$28.3 million in Q4 2025.
• The 3-year median for Consolidated Net Income is -$18.3 million (2024), against an average of -$18.9 million.
• The widest annual swing landed in 2025, when Consolidated Net Income increased 21.62%; it then plunged 50.18% in 2026.
• Tracing EVMN's Consolidated Net Income over 3 years: stood at -$20.7 million in 2024, then tumbled by 36.41% to -$28.3 million in 2025, then gained by 23.34% to -$21.7 million in 2026.
• Per Business Quant, the three latest EVMN Consolidated Net Income figures stand at -$21.7 million (Q1 2026), -$28.3 million (Q4 2025), and -$12.5 million (Q3 2025).

Peer Comparison